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Abstract
Background—We evaluated the efficacy of a maternal triple-drug antiretroviral regimen or
infant nevirapine prophylaxis for 28 weeks during breast-feeding to reduce postnatal transmission
of human immunodeficiency virus type 1 (HIV-1) in Malawi.
Methods—We randomly assigned 2369 HIV-1–positive, breast-feeding mothers with a CD4+
lymphocyte count of at least 250 cells per cubic millimeter and their infants to receive a maternal
antiretroviral regimen, infant nevirapine, or no extended postnatal antiretroviral regimen (control
group). All mothers and infants received perinatal prophylaxis with single-dose nevirapine and 1
week of zidovudine plus lamivudine. We used the Kaplan–Meier method to estimate the
cumulative risk of HIV-1 transmission or death by 28 weeks among infants who were HIV-1–
negative 2 weeks after birth. Rates were compared with the use of the log-rank test.
Results—Among mother–infant pairs, 5.0% of infants were HIV-1–positive at 2 weeks of life.
The estimated risk of HIV-1 transmission between 2 and 28 weeks was higher in the control group
(5.7%) than in either the maternal-regimen group (2.9%, P = 0.009) or the infant-regimen group
(1.7%, P<0.001). The estimated risk of infant HIV-1 infection or death between 2 and 28 weeks
was 7.0% in the control group, 4.1% in the maternal-regimen group (P = 0.02), and 2.6% in the
infant-regimen group (P<0.001). The proportion of women with neutropenia was higher among
those receiving the antiretroviral regimen (6.2%) than among those in either the nevirapine group
(2.6%) or the control group (2.3%). Among infants receiving nevirapine, 1.9% had a
hypersensitivity reaction.
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Conclusions—The use of either a maternal antiretroviral regimen or infant nevirapine for 28
weeks was effective in reducing HIV-1 transmission during breast-feeding. (ClinicalTrials.gov
number, NCT00164736.)
Approximately 200,000 infants worldwide become infected annually with human
immunodeficiency virus type 1 (HIV-1) through breast-feeding.1,2 Without treatment, half
of these infants will die before their second birthday.3 Although formula feeding decreases
the risk of postnatal HIV transmission, it is associated with an increased rate of early
death.4,5 Thus, exclusive breast-feeding is recommended by the World Health Organization
(WHO) for infants of HIV-1–positive women for the first 6 months of life in resource-
limited settings.6
The use of antiretroviral drugs during pregnancy, labor, and delivery effectively reduces
intrauterine and intrapartum HIV-1 transmission.7,8 However, without prophylaxis, an
additional 9% of HIV-1–negative infants who are born to HIV-1–positive mothers will
become infected after 18 months of breast-feeding.9 Several observational or uncontrolled
studies that have examined the use of either an extended maternal triple-drug regimen or
extended infant prophylaxis have suggested that these interventions reduce postnatal HIV-1
transmission.4,10–14 No studies to date have compared infant and maternal interventions.
Two clinical trials have shown that infant prophylaxis with daily nevirapine for either 6
weeks or 14 weeks during breast-feeding reduced early postnatal HIV transmission.15,16
The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study was a randomized, controlled
trial evaluating the safety and efficacy of a maternal triple-drug antiretroviral regimen or




The details of the methods that we used in this study have been described previously.17
Briefly, women were recruited at antenatal clinics in Lilongwe, Malawi, where HIV testing
is conducted.18 Primary eligibility criteria included an age of at least 14 years, a gestation of
30 weeks or less, a CD4+ lymphocyte count of at least 250 cells per cubic millimeter (≥200
cells per cubic millimeter before July 24, 2006), a hemoglobin level of at least 7 g per
deciliter, an alanine aminotransferase level of no more than 2.5 times the upper limit of the
normal range, and no serious complications of pregnancy. Women were excluded if they had
a serious infection or reported previous use of antiretroviral drugs during this or previous
pregnancies. After delivery, mother–infant pairs underwent randomization if they met
secondary eligibility criteria: a birth weight of a least 2000 g, no infant or maternal condition
that would preclude the use of a study drug, the mother’s acceptance of a 7-day maternal and
infant perinatal antiretroviral regimen, and enrollment within 36 hours after delivery. Infants
who were found to be HIV-1–positive by 2 weeks of life and their mothers were withdrawn
from the study and were referred for care.
The study’s protocol was approved by the Malawi National Health Science Research
Committee and the institutional review boards at the University of North Carolina at Chapel
Hill and the U.S. Centers for Disease Control and Prevention. All women provided written
informed consent.
Study Design and Interventions
After delivery, according to a permuted-block method, mother–infant pairs were randomly
assigned to a two-group nutritional intervention to promote maternal health and a three-
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group antiretroviral intervention — with drugs given to the mother (maternal-regimen
group), infant (infant-regimen group), or neither the mother nor the infant (control group) —
to prevent HIV-1 transmission during breast-feeding. Since there was no interaction between
the receipt of maternal nutritional supplementation and any of the antiviral interventions for
the primary study outcomes (the rate of infant HIV-1 infection or the composite outcome of
HIV-1 infection or death), this report focuses only on the antiretroviral intervention.
All mothers in labor and their newborn infants received a single dose of oral nevirapine.19 In
addition, all mothers received zidovudine and lamivudine as a single tablet (Combivir,
GlaxoSmithKline) containing 300 mg of zidovudine and 150 mg of lamivudine every 12
hours from the onset of labor to 7 days after birth. All infants also received twice-daily
zidovudine (2 mg per kilogram of body weight) and lamivudine (4 mg per kilogram) for 7
days.
All women were counseled to exclusively breastfeed followed by rapid weaning between 24
and 28 weeks postnatally. The interventions for both mothers and infants began after
delivery and were continued until the cessation of breastfeeding but no longer than 28
weeks.
Women in the maternal-regimen group initially received Combivir twice daily and
nevirapine at a dose of 200 mg once daily for 2 weeks and twice daily thereafter until 28
weeks. After the first 39 women were randomly assigned to the maternal-regimen group,
nevirapine was replaced with twice-daily nelfinavir (Viracept, Roche) at a dose of 1250 mg
for the next 146 women; nelfinavir was replaced with twice-daily lopinavir plus ritonavir
(Kaletra, Abbott), a combination of 400 mg of lopinavir and 100 mg of ritonavir, for the
remaining women. (The reason for this change was that in January 2005, the Food and Drug
Administration issued a black-box warning concerning the use of nevirapine in women with
a CD4+ lymphocyte count of more than 250 cells per cubic millimeter; at that time the study
team began using the second-line regimen containing nelfinavir; for reasons of availability,
safety, and potency, we then began using lopinavir plus ritonavir.17) Infants in the infant-
regimen group received a dose of nevirapine that increased according to age, ranging from
10 mg daily in the first 2 weeks to 30 mg daily for weeks 19 through 28. Adherence was
monitored by maternal self-report during five visits. Details regarding the management of
toxic effects are provided in the Supplementary Appendix, available with the full text of this
article at NEJM.org.
The study was conducted in accordance with the original protocol, except for the above-
mentioned replacement of nevirapine in the maternal-regimen group, the increase in the
CD4+ count from 200 to 250 per cubic millimeter as an entry criterion, and the addition of
trimethoprim–sulfamethoxazole prophylaxis for both mothers and infants. (Details are
available in the trial protocol, available at NEJM.org.)
Follow-up Visits and Study Procedures
Mother–infant pairs were followed at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 32, 36, 42, and 48
weeks after birth. A complete blood count and chemical analyses, including levels of alanine
aminotransferase, were obtained from mothers and infants at delivery and at 2, 6, 12, 18, 24,
28, 36, and 48 weeks. In addition, specimens from mothers were obtained antenatally at
screening and at weeks 4 and 8.
Study End Points
The primary efficacy end point was the rate of detection of HIV-1 infection at 28 weeks
among infants who were uninfected at 2 weeks and among all infants who underwent
randomization. Infants were tested for HIV-1 infection at birth and at 2, 12, 28, and 48
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weeks with the use of the Amplicor 1.5 DNA polymerase-chain-reaction (PCR) assay
(Roche Molecular Systems). Positive specimens were confirmed by testing a specimen
obtained at the next visit. If an infant was lost to follow-up or died before a confirmatory test
was obtained, then a second specimen from the same day was tested at the reference
laboratory at the University of North Carolina. Specimens with discrepant test results at the
local laboratory were retested at the reference laboratory. Final infection status was
determined by means of a review of test results by investigators who were unaware of study-
group assignments. The secondary efficacy end point was HIV-1–free survival by 28 weeks
among infants who were uninfected at 2 weeks and among all infants who underwent
randomization.
Clinical and laboratory adverse events were graded according to toxicity tables from the
Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID), as
revised in March 2006. A separate grading system was used for infant neutropenia because
of prevalent benign neutropenia among African infants, with a grade 3 toxicity defined as
less than 400 cells per cubic millimeter.20
On the basis of the fourth interim analysis, according to O’Brien–Fleming stopping
boundaries, the data and safety monitoring board for the Division of AIDS, which was
overseeing the study, halted enrollment in the control group on March 26, 2008, after 668 of
the planned 806 mother–infant pairs had been assigned to the control group.21
Study Oversight
GlaxoSmithKline, Abbott Laboratories, Boehringer Ingelheim, Roche Laboratories, and
Bristol-Myers Squibb provided the medications used in this study. The manufacturers had
no role in the design of the study, the collection or analysis of the data, or the decision to
submit the manuscript for publication. All authors vouch for the completeness and accuracy
of the data and the analyses.
Statistical Analysis
The Kaplan–Meier method was used to estimate the probability of each end point according
to the age of the infants, and differences between the intervention groups and the control
group were tested with the use of two-sided log-rank tests, stratified according to
randomization to the nutritional-supplementation groups. At 6, 12, 18, and 28 weeks, a two-
sided P value was computed for the z statistic on the basis of the difference between the
Kaplan–Meier estimates at that time point, with standard errors obtained with Greenwood’s
formula. The Cox proportional-hazards model was used to estimate hazard ratios and
confidence intervals for the study outcomes comparing the two intervention groups with the
control group, while adjusting for potentially prognostic baseline factors. Data regarding
infants who did not reach a study end point by 28 weeks were censored at the last negative
HIV-1 test or at 28 weeks, whichever occurred first. Data regarding mother–infant pairs who
switched to an intervention group after enrollment was halted in the control group were
censored at that time. To account for multiple comparisons with the control group, a P value
of less than 0.025 was considered to indicate statistical significance.
Results
Patients
Of the 3572 HIV-1–positive pregnant women who consented to undergo study screening,
3109 (87%) met the primary eligibility criteria. Of the 463 women (13%) who were
ineligible, 289 had a CD4+ count of less than either 200 cells or 250 cells per cubic
millimeter (depending on the study protocol at the time of enrollment). Of the eligible
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women, 2791 (90%) delivered an infant; 2382 mother–infant pairs met secondary eligibility
criteria, although 13 declined to participate in the study, leaving 2369 mother–infant pairs to
undergo randomization (Fig. 1).
Baseline demographic and laboratory characteristics of the 2369 mother–infant pairs who
underwent randomization were well balanced among the three groups (Table 1). Loss to
follow-up before 28 weeks occurred among 12% of mother–infant pairs in each study group.
On the basis of the mother’s adherence report over five follow-up visits, infants received
their prescribed nevirapine doses an average of 94% of the time, and mothers took their
prescribed antiretroviral doses 89% of the time. The self-reported frequency of exclusive
breast-feeding at 21 weeks after birth was 97% in the infant-nevirapine group and 96% in
both the maternal-therapy group and the control group. By 28 weeks, complete cessation of
breast-feeding was reported by 67 to 68% of mothers in each study group (Table 3 in the
Supplementary Appendix).
Infant HIV-1 Infection and Death
By 2 weeks, infants in each of the three study groups had a similar estimated risk of
infection: 5.4% (95% confidence interval [CI], 3.9 to 7.4) in the control group (reference
group), 5.5% (95% CI, 4.1 to 7.2; P = 0.97 with the use of a z statistic) in the maternal-
regimen group, and 4.4% (95% CI, 3.2 to 6.0; P = 0.35) in the infant-regimen group. Among
infants who were HIV-1–negative at 2 weeks, the estimated risk of HIV-1 infection by 28
weeks was 5.7% in the control group (reference group), 2.9% in the maternal-regimen
group, and 1.7% in the infant-regimen group (Table 2 and Fig. 2A). Among infants who
were HIV-1–negative at 2 weeks, there was a significant difference in the Kaplan–Meier
estimates of HIV-1 infection beginning at 6 weeks between the infant-regimen group and the
control group (P = 0.001 with the use of a z statistic), whereas the difference between the
control group and the maternal-regimen group reached borderline significance at 12 weeks
(P = 0.04 with the use of a z statistic) and significance at 18 weeks (P = 0.01). In an analysis
that included all infants who underwent randomization regardless of infection status at 2
weeks, the estimated risk of HIV-1 infection by 28 weeks was 10.9% (95% CI, 8.7 to 13.6)
in the control group, 8.2% (95% CI, 6.5 to 10.3) in the maternal-regimen group, and 6.0%
(95% CI, 4.5 to 7.8) in the infant-regimen group (Fig. 2C).
Between randomization and week 28, there were 37 infant deaths, of which 8 were among
HIV-1–positive infants. Six deaths among HIV-1–negative infants occurred less than 2
weeks after birth, a period that was not included in the primary analysis. Thus, there were 23
deaths among HIV-1–negative infants between weeks 2 and 28 (9 in the maternal-regimen
group, 7 in the infant-regimen group, and 7 in the control group). The causes of death among
all 37 infants were pneumonia (in 12 infants, of whom 5 were HIV-1–positive), sepsis (in 9
infants, of whom 1 was HIV-1–positive), meningitis (in 3 infants), diarrhea (in 2 infants),
malaria (in 1 HIV-1–positive infant), unknown causes (in 6 infants, of whom 1 was HIV-1–
positive), and drowning, diabetes insipidus, organophosphate poisoning, and severe anemia
presumably caused by trimethoprim–sulfamethoxazole toxicity in 1 infant each. (For details,
see Table 6 in the Supplementary Appendix.)
Among infants who were HIV-1–negative at 2 weeks, the estimated risk of infection or
death by 28 weeks was 7.0% in the control group (reference group), 4.1% in the maternal-
regimen group, and 2.6% in the infant-regimen group (Table 2 and Fig. 2B). Among all
infants who underwent randomization, the proportion who had died or were HIV-1–positive
by 28 weeks was 12.3% (95% CI, 10.0 to 15.2) in the control group (reference group), 9.6%
(95% CI, 7.7 to 11.8) in the maternal-regimen group, and 7.1% (95% CI, 5.5 to 9.1) in the
infant-regimen group (Fig. 2D). Although the study was not designed to compare the two
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intervention groups, there was a borderline indication that the rate of HIV-1–negative
survival among infants was greater when the infant received prophylaxis than when the
mother received the antiretroviral regimen (P = 0.07 by the log-rank test) (Fig. 2D).
Risk Factors for Infant HIV-1 infection
Both the maternal and infant regimens remained significantly associated with a reduced risk
of postnatal HIV-1 transmission after adjustment for maternal age and baseline CD4+ count
among infants who were HIV-1–negative at 2 weeks (Table 3). Both interventions also
remained associated with increased survival among HIV-1–negative infants. In addition,
among all infants, nevirapine prophylaxis remained significantly associated with a reduced
risk of postnatal HIV-1 transmission after multivariate adjustment for maternal age and
baseline CD4+ count (adjusted hazard ratio, 0.54; 95% CI, 0.37 to 0.78); the association
with the maternal regimen was of borderline significance (adjusted hazard ratio, 0.75; 95%
CI, 0.53 to 1.05). Since the medications that were used for the maternal regimen changed
over the course of the study, we examined the effect on transmission and HIV-1–negative
survival according to the type of regimen. A log-rank test comparing the three maternal drug
regimens suggested no difference in the rate of transmission by 28 weeks (for details, see the
Supplementary Appendix).
Serious Adverse Events
Among mothers receiving the antiretroviral regimen, grade 3 or 4 neutropenia developed in
6.2%, as compared with 2.6% in the infant-regimen group and 2.3% in the control group
(Table 4). Nevirapine hypersensitivity developed in 6 of 39 women who received a
nevirapine-based antiretroviral regimen (2 of whom had severe Stevens–Johnson syndrome).
Among the infants receiving nevirapine, a hypersensitivity reaction developed in 16 within 4
weeks after the initiation of therapy; this reaction resolved after nevirapine was replaced
with lamivudine. The hypersensitivity reactions in the infants consisted of rash and were
accompanied by eosinophilia in 10 of the infants, with or without fever. A similar reaction
developed in another infant whose mother was taking a nevirapine-containing antiretroviral
regimen. There were no between-group differences in other measurements of toxic effects
(Tables 4 and 5 in the Supplementary Appendix). The proportion of infants who had one or
more nonfatal serious adverse events was 12.6% in the control group, 14.0% in the
maternal-regimen group (P = 0.59), and 15.7% in the infant-regimen group (P = 0.15). The
proportion of mothers who had one or more serious adverse events was 2.7% in the control
group, 4.6% in the maternal-regimen group (P = 0.05), and 1.6% in the infant-regimen group
(P = 0.41). There were two maternal deaths (from tuberculosis and hepatic necrosis) in the
control group and none in the intervention groups.
Discussion
These data show that both a maternal antiretroviral regimen and infant nevirapine
prophylaxis during 28 weeks of breast-feeding were effective in reducing postnatal HIV-1
transmission, as compared with a control regimen of a single dose of nevirapine and 7 days
of zidovudine and lamivudine. The protective efficacy against HIV-1 transmission from 2 to
28 weeks was 74% for infant nevirapine and 53% for the maternal antiretroviral regimen.
Infants also had significantly increased HIV-1–negative survival with both interventions,
with a trend toward increased benefit when the drug regimen was administered directly to
the infant.
Previous studies have shown that when an antiretroviral regimen was started during the
antenatal period, rates of postnatal HIV-1 transmission of 1% or less by 6 months after birth
were achieved.10,11,14 Results of the observational Kisumu Breastfeeding Study
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(ClinicalTrials.gov number, NCT00146380) showed a transmission rate of 2.8% at 6
months.12 Our results suggest that the effect in the maternal-regimen group, which began 6
to 12 weeks after the effect in the infant-regimen group, could have reflected the time it took
for the viral load to be suppressed sufficiently to prevent transmission. In order to achieve
maximal reduction in HIV-1 transmission to the infant, the maternal regimen needs to start
antenatally.
Other randomized, controlled trials have shown the efficacy of the administration of
nevirapine to infants for the prevention of HIV-1 transmission during breast-feeding. In the
Six-Week Extended-Dose Nevirapine (SWEN) study (NCT00061321), the infection rate
among infants receiving 6 weeks of nevirapine was reduced from 9.0% to 6.9% at 6 months,
as compared with infants receiving single-dose nevirapine.15 The Post-Exposure
Prophylaxis of Infants (PEPI) study (NCT00115648) in Malawi showed a relative reduction
of 60% (95% CI, 42 to 73) in the rate of HIV-1 infection at 6 months among infants
receiving 14 weeks of nevirapine, as compared with infants receiving single-dose nevirapine
plus 1 week of zidovudine.16 Both the PEPI and SWEN studies included women with low
CD4+ counts, and some mothers initiated an antiretroviral regimen during the study. The
results of these studies suggest that an increased duration of nevirapine prophylaxis provides
greater protection and that infants may benefit from daily nevirapine prophylaxis throughout
breast-feeding without serious safety concerns. In an acknowledgment of the risk of weaning
infants at 6 months, as shown in recent studies,22,23 the WHO has modified its
recommendations to encourage breast-feeding for at least 12 months with more extended
prophylaxis.6
An important aspect of our study was the inclusion of both maternal and infant regimens for
the prevention of postnatal transmission. Infant nevirapine requires only a low-cost daily
dose and is associated with manageable toxic effects. In addition, the potential for resistance
is minimized, since a small proportion of infants receiving prophylaxis would become
infected, and they are unlikely to transmit the virus. On the other hand, the maternal regimen
may have advantages beyond simply protecting the infant, including maintaining maternal
health. However, treatment interruption or poor adherence may increase the risk of resistant
HIV-1 strains and restrict the mother’s future treatment options.24 Furthermore, the maternal
triple-drug regimen is costly and requires laboratory monitoring.25 Resistance may also
occur in infants who become infected while their mothers are receiving the triple-drug
regimen.26,27 Our finding of serious rashes in women with a high CD4+ count reinforces the
need to avoid nevirapine-based regimens in these women.
The best way to protect maternal health is to increase HIV-1 testing of pregnant women and
identify those in need of treatment. Women with a CD4+ count of less than 350 cells per
cubic millimeter should start the antiretroviral regimen antenatally. For women who do not
require treatment for their own health (i.e., those who have a CD4+ count of >350 cells per
cubic millimeter), either the infant or maternal regimen can be used to prevent the
transmission of HIV-1 in breast milk. In extremely resource-limited settings, nevirapine
prophylaxis for the infant throughout breast-feeding may be the regimen of choice for
reasons of cost, safety, and efficacy.
Health care providers and mothers can ultimately choose the option that best suits their
cultural, economic, and individual needs, since there is now evidence for two effective
options to prevent the transmission of HIV-1 to infants from their mothers during breast-
feeding in resource-limited countries.
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Figure 1. Enrollment and Outcomes
On March 26, 2008, the data and safety monitoring board stopped enrollment in the control
group after 668 of the planned 806 mother–infant pairs had been assigned to that group.
Hence, the numbers of patients who were enrolled in the three study groups were uneven. Of
the 29 infants who died during the study from non–HIV-1 causes, each had had a negative
test for HIV-1 before death.
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Figure 2. Kaplan–Meier Estimates of the Cumulative Risk of Infant HIV-1 Infection or a
Composite of HIV-1 Infection or Death by 28 Weeks
Shown is the probability of HIV-1 infection or a composite of HIV-1 infection or death
among infants who tested negative for HIV-1 infection at 2 weeks (Panels A and B) and
among all infants who underwent randomization (Panels C and D) in three groups of
mother–infants pairs: women who received an antiretroviral (ARV) regimen, infants who
received nevirapine (NVP) prophylaxis, and control subjects. Rates were compared with the
use of the log-rank test.
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Table 1







(N = 668) P Value*
Mothers
Age (yr)
      Median 26 25 26 0.72
      Interquartile range 22–29 22–30 22–29
Education beyond primary school (%) 35.4 36.3 31.5 0.12
Married (%) 92.6 93.1 92.7 0.90
Vaginal delivery (%) 93.6 93.2 92.2 0.55
Body-mass index <17 (%)† 0.66 0.13 0.17 0.16
CD4+ count per mm3
      Median 429 440 442 0.24
      Interquartile range 324–565 330–591 334–586
Hemoglobin (g/dl)
      Median 11 11 11 0.61
      Interquartile range 10–12 10–12 10–12
Infants
Male sex (%) 49.7 50.0 51.1 0.86
Birth weight (kg)
      Median 3.0 3.0 3.0 0.84
      Interquartile range 2.7–3.2 2.7–3.3 2.7–3.3
*
P values were calculated with the Kruskal–Wallis test for continuous variables and Fisher’s exact test for binary variables.
†
The body-mass index is the weight in kilograms divided by the square of the height in meters.
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Table 4









ALT ≥5× upper limit of normal range (%)   1.6   0.4   0.5
Hemoglobin <7.5 g/dl (%)   1.6   0.8   1.7
Neutrophil count <750 cells/mm3 (%)†   6.2   2.6   2.3
Platelet count <50,000/mm3 (%)   1.2   0.9   1.0
Nevirapine hypersensitivity (no.)‡   6   0   0
Infants
ALT ≥5× upper limit of normal range (%)   0.4   0.6   0.8
Reduced hemoglobin (%)§ 19.6 21.0 20.0
Neutrophil count <400 cells/mm3 (%)   0.5   1.1   0.7
Platelet count <50,000/mm3 (%)   1.1   1.0   1.5
Nevirapine hypersensitivity (no.)   1¶ 16   0
*
ALT denotes alanine aminotransferase.
†
P<0.001 for the comparison between the maternal-regimen group and the control group. No other comparisons between either of the intervention
groups and the control group were significant.
‡
In mothers, a nevirapine hypersensitivity reaction was defined as rash with one or more of the following: fever, hepatitis, arthralgias, or myalgias
during the first 6 to 8 weeks of nevirapine therapy. Severe Stevens–Johnson syndrome developed in two of the six women with hypersensitivity
reactions.
§
For HIV-1–negative infants, grade 3 or 4 adverse events with respect to hemoglobin were defined as less than 10 g per deciliter for infants
younger than 21 days, less than 8 g per deciliter for infants between the ages of 22 and 35 days, less than 7 g per deciliter for infants between the
ages of 36 and 56 days, and less than 9 g per deciliter for infants older than 56 days.
¶
In infants, a nevirapine hypersensitivity reaction was defined as rash alone of any grade or rash with eosinophilia, fever, or liver involvement and
was determined to be associated with nevirapine after the exclusion of other possible causes. The mother of this infant was receiving a nevirapine-
based regimen.
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